Interleukin-4 receptor

The interleukin-4 receptor (IL-4R) is a type I cytokine receptor that binds interleukin-4 (IL-4) and interleukin-13 (IL-13). It plays a crucial role in the immune system by mediating the effects of these cytokines, which are involved in the regulation of immune responses, particularly in allergic reactions and asthma.
Structure[edit]
The IL-4 receptor is a complex composed of multiple subunits. The primary subunit is the IL-4R_ chain, which is shared with the IL-13 receptor. The receptor can form two types of complexes: the type I receptor, which consists of IL-4R_ and the common gamma chain (_c), and the type II receptor, which consists of IL-4R_ and the IL-13R_1 chain.
Function[edit]
The IL-4 receptor is involved in the signaling pathways that lead to the differentiation of T helper 2 (Th2) cells, which are essential for the production of immunoglobulin E (IgE) and the promotion of B cell class switching. This receptor is also implicated in the regulation of macrophage activation and the modulation of inflammation.
Signaling Pathway[edit]
Upon binding of IL-4 or IL-13, the IL-4 receptor undergoes a conformational change that activates the associated Janus kinases (JAKs). This activation leads to the phosphorylation of the receptor and the recruitment of signal transducer and activator of transcription (STAT) proteins, particularly STAT6. Phosphorylated STAT6 dimerizes and translocates to the cell nucleus, where it acts as a transcription factor to regulate the expression of target genes involved in immune responses.
Clinical Significance[edit]
Dysregulation of IL-4 receptor signaling is associated with various allergic diseases, including asthma, atopic dermatitis, and allergic rhinitis. Therapeutic targeting of the IL-4 receptor, such as with monoclonal antibodies, is a strategy used in the treatment of these conditions. For example, dupilumab is a monoclonal antibody that inhibits IL-4 and IL-13 signaling by blocking the IL-4R_ subunit.
Research[edit]
Ongoing research is focused on understanding the detailed mechanisms of IL-4 receptor signaling and its role in immune regulation. Studies are also exploring the potential of IL-4 receptor antagonists in the treatment of other inflammatory and autoimmune diseases.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian